Fluoroquinolone‐Associated Tendinopathy: Does Levofloxacin Pose the Greatest Risk?

Pharmacotherapy - Tập 36 Số 6 - Trang 679-693 - 2016
Monique R. Bidell1, Thomas P. Lodise1
1Albany College of Pharmacy and Health Sciences, Albany, New York

Tóm tắt

Fluoroquinolone antibiotics recently have gained increased national attention due to safety concerns. A well‐described and serious adverse event associated with receipt of fluoroquinolones is tendinitis and tendon rupture. These tendon injuries can result in long‐term sequelae, including chronic pain and mobility restrictions, and may warrant surgery. Due to the severity of these adverse events, a black box warning is included in the product labeling of all fluoroquinolones. In light of the mounting concerns surrounding fluoroquinolone‐associated toxicities, the purpose of this clinical review is to provide a comprehensive summary of the risk of tendinopathy associated with levofloxacin, one of the most widely prescribed antibiotics in the United States, across in vitro, animal, and clinical studies, relative to other antibiotics. As part of this review, clinical presentation and onset, proposed mechanisms, patient‐specific risk factors, and management of fluoroquinolone‐induced tendon injury are summarized. Data were obtained from a comprehensive PubMed literature search and a review of U.S. Food and Drug Administration documents. Although tendinopathy is considered a fluoroquinolone class–wide toxicity, data from in vitro studies, animal studies, patient‐level analyses, and large national and international surveillance reports suggest that levofloxacin, as well as its parent compound ofloxacin, possess higher propensities to cause tendon damage relative to other fluoroquinolones. Risk with ofloxacin and levofloxacin appears to be exposure dependent, with higher doses and longer durations being most commonly associated with tendinopathy. Other well‐described patient risk factors for fluoroquinolone‐associated tendinopathy include older age (older than 60 yrs), receipt of concomitant corticosteroid therapy, presence of renal dysfunction, and history of solid organ transplantation. Given widespread use of levofloxacin across patient care settings, knowledge of both patient‐ and drug‐specific characteristics associated with increased risk of tendinitis and tendon rupture can promote safe use of levofloxacin and other fluoroquinolones.

Từ khóa


Tài liệu tham khảo

Antimicrobial Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee.FDA Briefing Document.2015. Available fromhttp://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/ucm467380.htm. Accessed March 20 2016.

10.1046/j.1365-2125.1999.00016.x

10.1086/375078

10.1046/j.1365-2125.1996.03013.x

10.1093/jac/dkt301

Ortho‐McNeil Pharmaceutical, 1998, Levaquin (levofloxacin) package insert

Ortho‐McNeil Pharmaceutical, 2004, Levaquin (levofloxacin) package insert

Pierfitte C, 1996, Tendon disorders with fluoroquinolones, Therapie, 51, 419

Janssen Pharmaceuticals, 2014, Levaquin (levofloxacin) package insert

10.1177/019262339702500615

10.1177/019262339202000313

10.1086/428055

10.1086/515104

Royer RJ, 1994, Features of tendon disorders with fluoroquinolones, Therapie, 49, 75

10.1007/s40264-013-0089-8

10.1001/archinte.163.15.1801

10.1111/j.1469-7580.2008.00864.x

10.1152/physrev.00031.2003

Sharma P, 2006, Biology of tendon injury: healing, modeling and remodeling, J Musculoskelet Neuronal Interact, 6, 181

10.1016/j.ijantimicag.2008.08.004

10.1016/j.ijantimicag.2009.10.009

10.1016/j.tox.2005.04.002

10.1097/JSA.0b013e3181a3d625

Maslanka T, 2004, Pathogenesis of quinolone‐induced arthropathy: a review of hypotheses, Pol J Vet Sci, 7, 323

10.1124/jpet.106.118224

10.1128/AAC.41.11.2389

10.2165/00003495-199500492-00075

10.1016/j.ejphar.2009.09.044

10.12659/MSM.892610

10.1128/AAC.00523-06

10.1007/BF02010725

10.1016/0041-008X(90)90144-J

10.1007/s150100070050

10.1159/000057842

10.1159/000057839

10.1002/1529-0131(200106)45:3<235::AID-ART254>3.3.CO;2-Z

10.1080/00365540310015863

10.2165/00002018-200326020-00004

10.1517/14740338.4.2.299

10.1002/pds.1214

10.2165/11536810-000000000-00000

10.1002/pds.3285

10.1517/14740338.2015.1085968

10.1345/aph.18298

10.1183/09031936.02.00257202

10.1136/bmj.324.7349.1306

10.2165/00002018-200629100-00006

10.1007/s00228-007-0265-9

10.1179/joc.2007.19.6.688

10.1016/j.healun.2007.09.021

Wise BL, 2012, Impact of age, sex, obesity, and steroid use on quinolone‐associated tendon disorders, Am J Med, 125, e23

10.1097/00007611-199906000-00014

10.2165/00003495-199958002-00009

10.3122/jabfm.16.5.458

10.3349/ymj.2010.51.3.454

10.1097/00007611-200093050-00008

Thông tin
Thông tin xuất bản

Pharmacotherapy

Tập 36 Số 6

679-693

Thông tin tác giả